151 related articles for article (PubMed ID: 30155949)
1. Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer.
Akgun E; Caliskan C; Bozbiyik O; Yoldas T; Sezak M; Ozkok S; Kose T; Karabulut B; Harman M; Ozutemiz O
Br J Surg; 2018 Oct; 105(11):1417-1425. PubMed ID: 30155949
[TBL] [Abstract][Full Text] [Related]
2. Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trial.
Akgun E; Caliskan C; Bozbiyik O; Yoldas T; Doganavsargil B; Ozkok S; Kose T; Karabulut B; Elmas N; Ozutemiz O
BJS Open; 2022 Sep; 6(5):. PubMed ID: 36254732
[TBL] [Abstract][Full Text] [Related]
3. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
4. [Effects of neoadjuvant chemoradiotherapy on the rates of sphincter preserving surgery in lower rectal cancer and analysis of their prognostic factors].
Wang XJ; Chi P; Lin HM; Lu XR; Huang Y; Xu ZB; Huang SH; Sun YW; Ye DX
Zhonghua Wai Ke Za Zhi; 2016 Jun; 54(6):419-423. PubMed ID: 27938574
[No Abstract] [Full Text] [Related]
5. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial.
Park JW; Kang SB; Hao J; Lim SB; Choi HS; Kim DW; Chang HJ; Kim DY; Jung KH; Kim TY; Kang GH; Chie EK; Kim SY; Sohn DK; Kim JS; Lee HS; Kim JH; Jeong SY; Oh JH
Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):569-577. PubMed ID: 33894918
[TBL] [Abstract][Full Text] [Related]
6. Oncologic Outcome and Morbidity in the Elderly Rectal Cancer Patients After Preoperative Chemoradiotherapy and Total Mesorectal Excision: A Multi-institutional and Case-matched Control Study.
Sung SY; Jang HS; Kim SH; Jeong JU; Jeong S; Song JH; Chung MJ; Cho HM; Kim HJ; Kim JG; Lee IK; Lee JH
Ann Surg; 2019 Jan; 269(1):108-113. PubMed ID: 28742692
[TBL] [Abstract][Full Text] [Related]
7. Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
Kitz J; Fokas E; Beissbarth T; Ströbel P; Wittekind C; Hartmann A; Rüschoff J; Papadopoulos T; Rösler E; Ortloff-Kittredge P; Kania U; Schlitt H; Link KH; Bechstein W; Raab HR; Staib L; Germer CT; Liersch T; Sauer R; Rödel C; Ghadimi M; Hohenberger W;
JAMA Surg; 2018 Aug; 153(8):e181607. PubMed ID: 29874375
[TBL] [Abstract][Full Text] [Related]
8. Tumour regression grading after chemoradiotherapy for locally advanced rectal cancer: a near pathologic complete response does not translate into good clinical outcome.
Swellengrebel HA; Bosch SL; Cats A; Vincent AD; Dewit LG; Verwaal VJ; Nagtegaal ID; Marijnen CA
Radiother Oncol; 2014 Jul; 112(1):44-51. PubMed ID: 25018000
[TBL] [Abstract][Full Text] [Related]
9. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer.
Sloothaak DA; Geijsen DE; van Leersum NJ; Punt CJ; Buskens CJ; Bemelman WA; Tanis PJ;
Br J Surg; 2013 Jun; 100(7):933-9. PubMed ID: 23536485
[TBL] [Abstract][Full Text] [Related]
10. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
[TBL] [Abstract][Full Text] [Related]
11. Delaying surgery after neoadjuvant chemoradiotherapy in rectal cancer has no influence in surgical approach or short-term clinical outcomes.
Figueiredo N; Panteleimonitis S; Popeskou S; Cunha JF; Qureshi T; Beets GL; Heald RJ; Parvaiz A
Eur J Surg Oncol; 2018 Apr; 44(4):484-489. PubMed ID: 29398323
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
[TBL] [Abstract][Full Text] [Related]
13. Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome.
Wolthuis AM; Penninckx F; Haustermans K; De Hertogh G; Fieuws S; Van Cutsem E; D'Hoore A
Ann Surg Oncol; 2012 Sep; 19(9):2833-41. PubMed ID: 22451236
[TBL] [Abstract][Full Text] [Related]
14. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers.
Lim SB; Choi HS; Jeong SY; Kim DY; Jung KH; Hong YS; Chang HJ; Park JG
Ann Surg; 2008 Aug; 248(2):243-51. PubMed ID: 18650634
[TBL] [Abstract][Full Text] [Related]
15. Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer.
Tural D; Ozturk M; Selcukbiricik F; Yildiz O; Elicin O; Turna H; Guney S; Ozguroglu M
J BUON; 2013; 18(2):385-90. PubMed ID: 23818350
[TBL] [Abstract][Full Text] [Related]
16. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
[TBL] [Abstract][Full Text] [Related]
17. Long-term prognostic impact of surgical complications in the German Rectal Cancer Trial CAO/ARO/AIO-94.
Sprenger T; Beißbarth T; Sauer R; Tschmelitsch J; Fietkau R; Liersch T; Hohenberger W; Staib L; Gaedcke J; Raab HR; Rödel C; Ghadimi M
Br J Surg; 2018 Oct; 105(11):1510-1518. PubMed ID: 29846017
[TBL] [Abstract][Full Text] [Related]
18. Use of sequential endorectal US to predict the tumor response of preoperative chemoradiotherapy in rectal cancer.
Li N; Dou L; Zhang Y; Jin J; Wang G; Xiao Q; Li Y; Wang X; Ren H; Fang H; Wang W; Wang S; Liu Y; Song Y
Gastrointest Endosc; 2017 Mar; 85(3):669-674. PubMed ID: 27354104
[TBL] [Abstract][Full Text] [Related]
19. Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies.
Petrelli F; Sgroi G; Sarti E; Barni S
Ann Surg; 2016 Mar; 263(3):458-64. PubMed ID: 24263329
[TBL] [Abstract][Full Text] [Related]
20. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy.
Lezoche E; Baldarelli M; Lezoche G; Paganini AM; Gesuita R; Guerrieri M
Br J Surg; 2012 Sep; 99(9):1211-8. PubMed ID: 22864880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
